Gossamer Bio Sees Unusually High Options Volume (NASDAQ:GOSS)

by · The Cerbat Gem

Gossamer Bio, Inc. (NASDAQ:GOSS – Get Free Report) was the recipient of unusually large options trading on Monday. Traders acquired 23,621 call options on the stock. This is an increase of approximately 882% compared to the average volume of 2,406 call options.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on GOSS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Gossamer Bio in a research note on Wednesday, October 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Gossamer Bio in a research note on Thursday, September 11th. Finally, Wall Street Zen upgraded Gossamer Bio from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Gossamer Bio has an average rating of “Moderate Buy” and an average price target of $8.50.

Get Our Latest Analysis on GOSS

Gossamer Bio Stock Performance

Shares of Gossamer Bio stock traded up $0.14 during trading hours on Monday, reaching $3.74. The company’s stock had a trading volume of 6,036,664 shares, compared to its average volume of 2,504,695. The company has a market capitalization of $864.50 million, a P/E ratio of -5.41 and a beta of 1.92. The stock’s fifty day simple moving average is $2.75 and its two-hundred day simple moving average is $2.25. Gossamer Bio has a one year low of $0.76 and a one year high of $3.87.

Gossamer Bio (NASDAQ:GOSS – Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Gossamer Bio had a negative net margin of 354.50% and a negative return on equity of 1,774.72%. The company had revenue of $13.29 million during the quarter, compared to the consensus estimate of $6.32 million. As a group, research analysts forecast that Gossamer Bio will post -0.28 earnings per share for the current year.

Hedge Funds Weigh In On Gossamer Bio

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Millennium Management LLC grew its stake in Gossamer Bio by 629.3% during the third quarter. Millennium Management LLC now owns 3,619,329 shares of the company’s stock valued at $9,519,000 after acquiring an additional 3,123,081 shares in the last quarter. Bank of America Corp DE increased its stake in Gossamer Bio by 4,196.2% in the third quarter. Bank of America Corp DE now owns 2,881,904 shares of the company’s stock valued at $7,579,000 after acquiring an additional 2,814,824 shares during the last quarter. UBS Group AG raised its position in Gossamer Bio by 785.7% during the third quarter. UBS Group AG now owns 2,770,046 shares of the company’s stock valued at $7,285,000 after purchasing an additional 2,457,304 shares in the last quarter. Geode Capital Management LLC lifted its stake in Gossamer Bio by 100.4% during the second quarter. Geode Capital Management LLC now owns 4,555,080 shares of the company’s stock worth $5,604,000 after purchasing an additional 2,282,632 shares during the last quarter. Finally, MB Generational Wealth LLC bought a new stake in Gossamer Bio during the third quarter worth about $3,721,000. 81.23% of the stock is owned by hedge funds and other institutional investors.

About Gossamer Bio

(Get Free Report)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

See Also